Abstract
1 The results so far published in the literature, together with our own results, show that in clobazam (Frisium) we have a daytime tranquilizer which is comparable to the newest benzodiazepine derivatives. 2 It is particularly indicated in disorders of the sleeping-waking rhythm, and sometimes also in psychovegetative disorders associated with epilepsy. 3. Its tranquillizing profile of action, the low incidence of side-effects and the absence of interactions with other drugs mean that its applications are varied, not only in neuropsychiatry but also in other medical disciplines. 4 The fact that therapeutic doses do not seem to impair driving ability to render patients incapable of carrying on their profession, means that it is suitable for the treatment of outpatients.